SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ron L.H. Handels, Claire A.G. Wolfs, Pauline Aalten, Manuela A. Joore, Frans R.J. Verhey, Johan L. Severens, Diagnosing Alzheimer's disease: A systematic review of economic evaluations, Alzheimer's & Dementia, 2014, 10, 2, 225

    CrossRef

  2. 2
    Thomas Rapp, Patients' diagnosis decisions in Alzheimer's disease: The influence of family factors, Social Science & Medicine, 2014, 118, 9

    CrossRef

  3. 3
    J. Scott Roberts, Sara J. McLaughlin, Cathleen M Connell, Public beliefs and knowledge about risk and protective factors for Alzheimer's disease, Alzheimer's & Dementia, 2014,

    CrossRef

  4. 4
    Gail P. Jarvik, Laura M. Amendola, Jonathan S. Berg, Kyle Brothers, Ellen W. Clayton, Wendy Chung, Barbara J. Evans, James P. Evans, Stephanie M. Fullerton, Carlos J. Gallego, Nanibaa’ A. Garrison, Stacy W. Gray, Ingrid A. Holm, Iftikhar J. Kullo, Lisa Soleymani Lehmann, Cathy McCarty, Cynthia A. Prows, Heidi L. Rehm, Richard R. Sharp, Joseph Salama, Saskia Sanderson, Sara L. Van Driest, Marc S. Williams, Susan M. Wolf, Wendy A. Wolf, Wylie Burke, Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between, The American Journal of Human Genetics, 2014, 94, 6, 818

    CrossRef

  5. 5
    Maria Gazouli, Kyriakos Souliotis, The Economic Considerations and Implications of the Stratification of Future Oncology Therapeutics, Molecular Diagnosis & Therapy, 2014, 18, 4, 403

    CrossRef

  6. 6
    Sandy Tubeuf, Thomas A Willis, Barbara Potrata, Hilary Grant, Matthew J Allsop, Mushtaq Ahmed, Jenny Hewison, Martin McKibbin, Willingness to pay for genetic testing for inherited retinal disease, European Journal of Human Genetics, 2014,

    CrossRef

  7. 7
    Kara-Grace Leventhal, William Tuong, Beth N. Peshkin, Yasmin Salehizadeh, Mary B. Fishman, Susan Eggly, Kevin FitzGerald, Marc D. Schwartz, Kristi D. Graves, “Is it Really Worth it to Get Tested?”: Primary Care Patients’ Impressions of Predictive SNP Testing for Colon Cancer, Journal of Genetic Counseling, 2013, 22, 1, 138

    CrossRef

  8. 8
    Jane S. Paulsen, Martha Nance, Ji-In Kim, Noelle E. Carlozzi, Peter K. Panegyres, Cheryl Erwin, Anita Goh, Elizabeth McCusker, Janet K. Williams, A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases, Progress in Neurobiology, 2013, 110, 2

    CrossRef

  9. 9
    J Scott Roberts, Laura B Dunn, Gil D Rabinovici, Amyloid imaging, risk disclosure and Alzheimer’s disease: ethical and practical issues, Neurodegenerative Disease Management, 2013, 3, 3, 219

    CrossRef

  10. 10
    Michael Drummond, Rosanna Tarricone, Aleksandra Torbica, Assessing the Added Value of Health Technologies: Reconciling Different Perspectives, Value in Health, 2013, 16, 1, S7

    CrossRef

  11. 11
    Martina Garau, Adrian Towse, Louis Garrison, Laura Housman, Diego Ossa, Can and should value-based pricing be applied to molecular diagnostics?, Personalized Medicine, 2013, 10, 1, 61

    CrossRef

  12. 12
    John Hornberger, Irina Degtiar, Hialy Gutierrez, Ashwini Shewade, W. David Henner, Shawn Becker, Gauri Varadachary, Stephen Raab, Cost-Effectiveness of Gene-Expression Profiling for Tumor-Site Origin, Value in Health, 2013, 16, 1, 46

    CrossRef

  13. 13
    Pei-Jung Lin, Thomas W Concannon, Dan Greenberg, Joshua T Cohen, Gregory Rossi, Jeffrey Hille, Hannah R Auerbach, Chi-Hui Fang, Eric S Nadler, Peter J Neumann, Does framing of cancer survival affect perceived value of care? A willingness-to-pay survey of US residents, Expert Review of Pharmacoeconomics & Outcomes Research, 2013, 13, 4, 513

    CrossRef

  14. 14
    Adrian Towse, Louis P. Garrison, Economic Incentives for Evidence Generation: Promoting an Efficient Path to Personalized Medicine, Value in Health, 2013, 16, 6, S39

    CrossRef

  15. 15
    J. Scott Roberts, Wendy R. Uhlmann, Genetic susceptibility testing for neurodegenerative diseases: Ethical and practice issues, Progress in Neurobiology, 2013, 110, 89

    CrossRef

  16. You have free access to this content16
    Brian R. Edlin, Hepatitis C screening: Getting it right, Hepatology, 2013, 57, 4
  17. 17
    D. E. Newman-Toker, K. M. McDonald, D. O. Meltzer, N.-T. DE, B. GT, L. HP, A. EM, C. A, F. KD, How much diagnostic safety can we afford, and how should we decide? A health economics perspective, BMJ Quality & Safety, 2013, 22, Suppl 2, ii11

    CrossRef

  18. 18
    E. Vermeulen, L. Henneman, C. G. van El, M. C. Cornel, Public attitudes towards preventive genomics and personal interest in genetic testing to prevent disease: a survey study, The European Journal of Public Health, 2013,

    CrossRef

  19. 19
    Pei-Jung Lin, Michael J. Cangelosi, David W. Lee, Peter J. Neumann, Willingness to Pay for Diagnostic Technologies: A Review of the Contingent Valuation Literature, Value in Health, 2013, 16, 5, 797

    CrossRef

  20. 20
    Elizabeth M Wikler, Robert J Blendon, John M Benson, Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease, Alzheimer's Research & Therapy, 2013, 5, 5, 43

    CrossRef

  21. 21
    Andrea Anonychuk, Graham Beastall, Simon Shorter, Regina Kloss-Wolf, Peter Neumann, A framework for assessing the value of laboratory diagnostics, Healthcare Management Forum, 2012, 25, 3, S4

    CrossRef

  22. 22
    Katrina A.B. Goddard, William A. Knaus, Evelyn Whitlock, Gary H. Lyman, Heather Spencer Feigelson, Sheri D. Schully, Scott Ramsey, Sean Tunis, Andrew N. Freedman, Muin J. Khoury, David L. Veenstra, Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research, Genetics in Medicine, 2012, 14, 7, 633

    CrossRef

  23. 23
    Ruth Saunders, Richard E. Ashcroft, Consumer genetics and addiction susceptibility testing—just what the consumer ordered, Addiction, 2012, 107, 12
  24. 24
    Timothy Caulfield, Amy L. McGuire, Direct-to-Consumer Genetic Testing: Perceptions, Problems, and Policy Responses, Annual Review of Medicine, 2012, 63, 1, 23

    CrossRef

  25. 25
    Shien Guo, Denis Getsios, Luis Hernandez, Kelly Cho, Elizabeth Lawler, Arman Altincatal, Stephan Lanes, Michael Blankenburg, Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps, International Journal of Alzheimer's Disease, 2012, 2012, 1

    CrossRef

  26. 26
    J Scott Roberts, Genetic testing for risk of Alzheimer’s disease: benefit or burden?, Neurodegenerative Disease Management, 2012, 2, 2, 141

    CrossRef

  27. 27
    Katherine Wasson, Nancy S. Hogan, Tonya Nashay Sanders, Kathy J. Helzlsouer, Primary Care Patients’ Views, Attitudes, and Decision-Making Factors Regarding Direct-to-Consumer Personal Genome Testing: Results From a Qualitative Study, AJOB Primary Research, 2012, 3, 2, 24

    CrossRef

  28. 28
    Andrea Anonychuk, Graham Beastall, Simon Shorter, Regina Kloss-Wolf, Peter Neumann, Un cadre pour évaluer la valeur des diagnostics en laboratoire, Healthcare Management Forum, 2012, 25, 3, S12

    CrossRef